Related Experiment Video

Updated: Sep 23, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumococcal infection in children: rational antibiotic choice for drug-resistant Streptococcus pneumoniae

Christine C Chiou1, Kai-Sheng Hseih

  • 1Department of Pediatrics, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung First Road, Kaohsiung, Taiwan.

Acta Paediatrica Taiwanica = Taiwan Er Ke Yi Xue Hui Za Zhi
|July 9, 2003
PubMed

Insights

Penicillin-resistant Streptococcus pneumoniae is a growing concern, especially in children. Treatment strategies must consider infection site and resistance level, as beta-lactamase inhibitors are ineffective against this common pathogen.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pediatrics

Background:

  • Streptococcus pneumoniae is a leading cause of pediatric infections like pneumonia and meningitis.
  • Increasing antimicrobial resistance, particularly to penicillin, poses a significant global health challenge.
  • Taiwan reports a high prevalence (70%) of penicillin-resistant S. pneumoniae in children.

Purpose of the Study:

  • To address the challenge of penicillin-resistant Streptococcus pneumoniae infections.
  • To highlight the mechanism of penicillin resistance in S. pneumoniae.
  • To guide appropriate treatment strategies for S. pneumoniae infections based on resistance patterns.

Main Methods:

  • Review of existing literature on Streptococcus pneumoniae resistance mechanisms.
  • Analysis of antimicrobial susceptibility data and clinical breakpoints.
  • Evaluation of treatment guidelines for S. pneumoniae infections.

Main Results:

  • Penicillin resistance in S. pneumoniae is primarily due to altered penicillin-binding proteins (PBPs), not beta-lactamase production.
  • Beta-lactamase inhibitors are ineffective against penicillin-resistant S. pneumoniae.
  • Treatment decisions for S. pneumoniae infections require consideration of infection site and degree of resistance.

Conclusions:

  • Effective treatment of penicillin-resistant S. pneumoniae necessitates tailored approaches.
  • Penicillin remains a viable option for susceptible or intermediate non-CNS infections.
  • Vancomycin should not be the empirical first-line treatment for all pneumococcal infections.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...